Roche Bets Big on Obesity Drug Market with 89bio Buy

Roche just made a $3.5 billion power play to grab 89bio, a San Francisco biotech firm, aiming to conquer the lucrative weight-loss drug market and tackle MASH liver disease. This acquisition could catapult Roche into competition with giants like Eli Lilly and Novo Nordisk, potentially adding $2 billion annually to their revenue by 2030 with 89bio's lead drug. It's a bold move to expand Roche's metabolic disease pipeline, following previous acquisitions, and 89bio's stock is already soaring. Hosted on Acast. See acast.com/privacy for more information.